Amorphical Names Eden Ben as CEO to Advance Nano-Amorphous Mineral Therapeutics
NES ZIONA, Israel – September 2, 2025 – Amorphical, a developer of nano-amorphous mineral-based therapies, today announced the appointment of Eden Ben as Chief Executive Officer. Ben will lead the company’s next phase of growth as it accelerates its regulatory strategy in the U.S. and Europe and advances a pipeline of disease-modifying treatments targeting serious health conditions including hypoparathyroidism, pancreatic cancer, osteoporotic fractures, and Crohn’s disease.
Amorphical’s proprietary nano-amorphous mineral technology delivers unique benefits by regulating cellular pH and achieving superior bioavailability compared to conventional mineral formulations. This platform underpins the company’s efforts to move beyond symptom management and develop therapies that address the root causes of disease, representing a significant opportunity across oncology, endocrine disorders, and musculoskeletal health.
“Our nano-amorphous mineral technology, which is over a million times smaller than traditional mineral forms, represents a new frontier in medicine,” said Eden Ben, CEO of Amorphical. “We are focused on delivering safe, effective therapies with the potential to transform outcomes for patients worldwide.”
Advancing Through Clinical Development
Amorphical’s approach is supported by more than a decade of real-world experience through early access and compassionate use programs, providing insights into safety, tolerability, and patient-reported outcomes.
The company is currently conducting a Phase 2 trial for hypoparathyroidism under U.S. Food and Drug Administration (FDA) oversight. Additional studies for pancreatic cancer, Crohn’s disease, and osteoporotic fractures are under review with global regulatory bodies.
Amorphical’s fully GMP-compliant manufacturing facility provides the infrastructure to scale production and support global clinical and commercial launches as the pipeline progresses.
“Eden’s expertise is perfectly aligned with Amorphical’s mission to deliver safe and breakthrough nano-amorphous mineral treatments for serious diseases,” said Ran Gorelik, Board Member, Amorphical. “His leadership comes at a pivotal time as we advance development, regulatory, and clinical milestones.”
With Ben’s appointment, Amorphical aims to accelerate the delivery of scientifically validated, nature-inspired therapies to patients, positioning itself at the forefront of innovation in oncology, metabolic disease, and musculoskeletal health.
